drugset
drugset / Trial / NCT03815071

A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells

NCT03815071 ↗

Phase 0 Unknown 10 enrolled Allife Medical Science and Technology Co., Ltd. Beijing Hospital · collabHenan Provincial People's Hospital · collabThe First People's Hospital of Yunnan · collab
NaSingle-groupOpen-labelHealth-services research

Summary

This is a single center, single arm and open-label study to investigate the safety and efficacy of iPS-NCS with Parkinson's Disease

Timeline

Start
2019-02-01
Primary completion
2020-02-01
Completion
2021-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject iPS-NCS Unknown — —

Indications

Parkinson disease